BIOTE CORP -A (BTMD) Stock Fundamental Analysis

NASDAQ:BTMD • US0906831039

2.06 USD
+0.01 (+0.49%)
At close: Feb 24, 2026
2.06 USD
0 (0%)
After Hours: 2/24/2026, 8:12:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

BTMD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. BTMD has only an average score on both its financial health and profitability. BTMD scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year BTMD was profitable.
  • In the past year BTMD had a positive cash flow from operations.
  • BTMD had positive earnings in 4 of the past 5 years.
  • BTMD had a positive operating cash flow in 4 of the past 5 years.
BTMD Yearly Net Income VS EBIT VS OCF VS FCFBTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 25.87%, BTMD belongs to the top of the industry, outperforming 98.44% of the companies in the same industry.
  • BTMD has a better Return On Invested Capital (45.22%) than 99.48% of its industry peers.
Industry RankSector Rank
ROA 25.87%
ROE N/A
ROIC 45.22%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTMD Yearly ROA, ROE, ROICBTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

  • Looking at the Profit Margin, with a value of 14.72%, BTMD belongs to the top of the industry, outperforming 86.98% of the companies in the same industry.
  • In the last couple of years the Profit Margin of BTMD has declined.
  • With an excellent Operating Margin value of 16.09%, BTMD belongs to the best of the industry, outperforming 86.46% of the companies in the same industry.
  • BTMD's Operating Margin has declined in the last couple of years.
  • BTMD has a better Gross Margin (72.23%) than 79.69% of its industry peers.
  • In the last couple of years the Gross Margin of BTMD has grown nicely.
Industry RankSector Rank
OM 16.09%
PM (TTM) 14.72%
GM 72.23%
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
BTMD Yearly Profit, Operating, Gross MarginsBTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • BTMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for BTMD has been reduced compared to 1 year ago.
  • Compared to 1 year ago, BTMD has a worse debt to assets ratio.
BTMD Yearly Shares OutstandingBTMD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
BTMD Yearly Total Debt VS Total AssetsBTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • BTMD has an Altman-Z score of 2.20. This is not the best score and indicates that BTMD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.20, BTMD is doing good in the industry, outperforming 63.54% of the companies in the same industry.
  • BTMD has a debt to FCF ratio of 4.18. This is a neutral value as BTMD would need 4.18 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 4.18, BTMD belongs to the best of the industry, outperforming 85.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.18
Altman-Z 2.2
ROIC/WACC4.88
WACC9.26%
BTMD Yearly LT Debt VS Equity VS FCFBTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 1.01 indicates that BTMD should not have too much problems paying its short term obligations.
  • The Current ratio of BTMD (1.01) is worse than 83.85% of its industry peers.
  • BTMD has a Quick Ratio of 1.01. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BTMD has a Quick ratio of 0.72. This is amonst the worse of the industry: BTMD underperforms 84.38% of its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 0.72
BTMD Yearly Current Assets VS Current LiabilitesBTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 190.00%, which is quite impressive.
  • BTMD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -48.53% yearly.
  • Looking at the last year, BTMD shows a very negative growth in Revenue. The Revenue has decreased by -18.44% in the last year.
  • Measured over the past years, BTMD shows a quite strong growth in Revenue. The Revenue has been growing by 12.38% on average per year.
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%

3.2 Future

  • The Earnings Per Share is expected to grow by 41.42% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, BTMD will show a small growth in Revenue. The Revenue will grow by 6.89% on average per year.
EPS Next Y229.18%
EPS Next 2Y7.66%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue Next Year-3.44%
Revenue Next 2Y-0.58%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BTMD Yearly Revenue VS EstimatesBTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
BTMD Yearly EPS VS EstimatesBTMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 2.37, which indicates a rather cheap valuation of BTMD.
  • Compared to the rest of the industry, the Price/Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 98.44% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.98, BTMD is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 8.08, the valuation of BTMD can be described as reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 91.67% of the companies listed in the same industry.
  • BTMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.01, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 2.37
Fwd PE 8.08
BTMD Price Earnings VS Forward Price EarningsBTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • BTMD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BTMD is cheaper than 96.35% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BTMD is valued cheaper than 98.96% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.73
EV/EBITDA 5.94
BTMD Per share dataBTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • BTMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of BTMD may justify a higher PE ratio.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y7.66%
EPS Next 3Y9.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BTMD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOTE CORP -A

NASDAQ:BTMD (2/24/2026, 8:12:03 PM)

After market: 2.06 0 (0%)

2.06

+0.01 (+0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)03-18
Inst Owners63.14%
Inst Owner Change0.4%
Ins Owners10.06%
Ins Owner Change0%
Market Cap94.06M
Revenue(TTM)195.65M
Net Income(TTM)28.79M
Analysts81.82
Price Target4.94 (139.81%)
Short Float %5.79%
Short Ratio10.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)270.4%
Min EPS beat(2)178.65%
Max EPS beat(2)362.15%
EPS beat(4)3
Avg EPS beat(4)249.23%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)105.05%
EPS beat(12)7
Avg EPS beat(12)16.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.43%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-1.55%
Revenue beat(4)1
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.65%
Revenue beat(12)4
Avg Revenue beat(12)-1.32%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.08%
EPS NY rev (1m)0%
EPS NY rev (3m)23.48%
Revenue NQ rev (1m)0.87%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.52%
Valuation
Industry RankSector Rank
PE 2.37
Fwd PE 8.08
P/S 0.48
P/FCF 2.73
P/OCF 2.35
P/B N/A
P/tB N/A
EV/EBITDA 5.94
EPS(TTM)0.87
EY42.23%
EPS(NY)0.26
Fwd EY12.38%
FCF(TTM)0.75
FCFY36.59%
OCF(TTM)0.88
OCFY42.52%
SpS4.28
BVpS-1.59
TBVpS-1.9
PEG (NY)0.01
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 25.87%
ROE N/A
ROCE 57.24%
ROIC 45.22%
ROICexc 92.24%
ROICexgc 190.38%
OM 16.09%
PM (TTM) 14.72%
GM 72.23%
FCFM 17.59%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score7
Asset Turnover1.76
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.18
Debt/EBITDA 3.02
Cap/Depr 144.67%
Cap/Sales 2.85%
Interest Coverage 3.81
Cash Conversion 113.15%
Profit Quality 119.51%
Current Ratio 1.01
Quick Ratio 0.72
Altman-Z 2.2
F-Score7
WACC9.26%
ROIC/WACC4.88
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
EPS Next Y229.18%
EPS Next 2Y7.66%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
Revenue Next Year-3.44%
Revenue Next 2Y-0.58%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%
EBIT growth 1Y-29.68%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year30.98%
EBIT Next 3Y13.56%
EBIT Next 5Y13.39%
FCF growth 1Y43.63%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y53.94%
OCF growth 3Y10.29%
OCF growth 5Y12.28%

BIOTE CORP -A / BTMD FAQ

Can you provide the ChartMill fundamental rating for BIOTE CORP -A?

ChartMill assigns a fundamental rating of 5 / 10 to BTMD.


Can you provide the valuation status for BIOTE CORP -A?

ChartMill assigns a valuation rating of 9 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.


Can you provide the profitability details for BIOTE CORP -A?

BIOTE CORP -A (BTMD) has a profitability rating of 6 / 10.


How financially healthy is BIOTE CORP -A?

The financial health rating of BIOTE CORP -A (BTMD) is 4 / 10.


How sustainable is the dividend of BIOTE CORP -A (BTMD) stock?

The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.